ClinicalTrials.gg
Not yet recruitingNCT07774728HBD-RCTUpdated Nov 6, 2026

Hearing Intervention Effects on Brain and Language Development in Children With Bilateral Mild Hearing Loss

An interventional study of Behind-the-ear (BTE) hearing aids and Hearing-care educational sessions in Hearing Loss, Bilateral, sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University. Not yet recruiting at 12 sites in China. Open to participants aged 6 Months to 4 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Not applicable, Interventional, and Treatment

Updated Nov 6, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
6 Months to 4 Years
Sex
All
01

Study summary

This is a multicenter, prospective, randomized controlled clinical trial to evaluate the effects of hearing aid intervention on brain and language development in children with bilateral mild sensorineural hearing loss. Eligible participants will be randomly assigned (1:1) to either the hearing aid intervention group or the control group. The primary outcome is the general developmental quotient of the Griffiths Development Scales-Chinese Edition (GDS-C) at 12 months. Secondary outcomes include auditory and speech development, language development, adaptive behavior, and brain structure and function assessed by MRI. Follow-up assessments will be conducted at baseline, 6 months, and 12 months.

02

Conditions studied

  • Hearing Loss, Bilateral

Keywords

  • Mild hearing loss
  • Hearing aids
  • Brain development
  • Children
03

In context

Hearing Loss, Bilateral

55 studies on the registry are indexed under Hearing Loss, Bilateral; 17 are open to participants now.

This study's planned enrollment of 260 is above the median of 30 across 42 interventional studies indexed under Hearing Loss, Bilateral.

Browse Hearing Loss, Bilateral studies →

Lead sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University is the lead sponsor of 164 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 4 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: ≥0.5 years and \<4 years
  • Diagnosed with bilateral mild sensorineural hearing loss by objective hearing tests: bilateral click-ABR ≥35 dB nHL and ≤50 dB nHL, with bilateral type A tympanogram (including As/Ad type) on acoustic immittance testing
  • Without previous hearing aid intervention

Exclusion criteria

Exclusion Criteria:

  • Premature and low birth weight infants: gestational age less than 37 weeks, or birth weight below 2500 grams
  • Participants diagnosed with enlarged vestibular aqueduct (EVA) by imaging (CT, MRI) or genetic testing
  • Participants with complicated medical problems or significant disabilities affecting growth and development (such as autism, recurrent epilepsy, severe heart disease requiring multiple surgeries, etc.) and considered unsuitable for this study by the investigators
  • Families who refused to participate in this study, or have already decided whether the participant will wear hearing aids or not (refused to randomization).
  • Participants who refused/was unable to undergo study assessments as scheduled.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Hearing-aid intervention

    Participants in the hearing-aid intervention group will receive standardized bilateral fitting of behind-the-ear (BTE) hearing aids, and their parents will be instructed to ensure consistent daily use for 12 months and be provided with essential knowledge regarding hearing aid maintenance and proper usage. In addition, the same hearing-care education sessions will also be delivered to this group.

    Device: Behind-the-ear (BTE) hearing aids · Other: Hearing-care educational sessions

  • Other
    Hearing-care education

    Participants in the hearing-care education control group will not receive hearing aids, but will receive standardized hearing-care educational sessions at each follow-up visit.

    Other: Hearing-care educational sessions

Interventions

  • DeviceBehind-the-ear (BTE) hearing aids

    Bilateral BTE hearing aids will be uniformly provided by the project team and fitted and verified by experienced audiologists at participating sites, with settings adjusted to achieve optimal hearing status according to individual needs. The devices will be selected from mainstream BTE hearing aid brands and models that are already commercially available in China and widely used in pediatric populations.

  • OtherHearing-care educational sessions

    Standardized educational sessions covering children hearing and speech development, pediatric hearing care, routine monitoring and detection, and appropriate family support and parent-child interaction delivered by trained researchers during each follow-up visit.

06

What researchers measure

Primary outcomes

  1. Children overall development, as measured by General Developmental Quotient (GDQ) from the Griffiths Development Scales - Chinese Edition (GDS-C)

    The GDS-C was adapted from the 2006 Griffiths Mental Development Scales - Extended Revised (GMDS-ER) and standardized with Chinese norms for children aged 0-8 years. It evaluates six subdomains: (A) Locomotor, (B) Personal-Social, (C) Language, (D) Eye \& Hand Coordination, (E) Performance, and (F) Practical Reasoning. The General Developmental Quotient (GDQ) is derived as:(developmental age ÷ chronological age) × 100. Higher scores indicate better overall developmental status.

    Time frame: From enrollment to 12 months, with assessments at 0, 6, and 12 months.

Secondary outcomes

  1. Griffiths Development Scales-Chinese Edition (GDS-C) subscale quotients

    Including six subscales: Locomotor (A), Personal-Social (B), Language (C), Eye-hand Co-ordination (D), Performance (E), and Practical Reasoning (F). Each subscale quotient is calculated as (subscale developmental age ÷ chronological age) × 100. Higher subscale quotients indicate better performance in the specific domain.

    Time frame: From enrollment to 12 months, with assessments at 0, 6, and 12 months.

  2. MRI outcomes

    Brain structure and function changes evaluated by MRI

    Time frame: Assessed at 0 and 12 months.

  3. Auditory Brainstem Response (ABR)

    Electrical potentials recorded with scalp electrodes in response to electrical stimulation of the cochlear nerve. The ABR threshold will be measured in decibels normal hearing level (dB nHL) for each ear. Lower thresholds indicate better auditory function.

    Time frame: From enrollment to 12 months, with assessments at 0, 6, and 12 months.

  4. Behavioral audiometry thresholds (Pure-Tone Audiometry)

    Behavioral audiometry measures the lowest pure tone level children can respond. Its thresholds will be measured in decibels hearing level (dB HL) for each ear at standard frequencies. The Pure Tone Average (PTA) will be calculated by the average of four frequencies (0.5, 1, 2, 4 kHz). Lower thresholds indicate better hearing.

    Time frame: From enrollment to 12 months, with assessments at 0, 6, and 12 months.

  5. Word Recognition Score

    Measured by percentage of correctly identified words (ranging from 0% to 100%) from standardized Mandarin Chinese word lists, presented in a quiet sound booth. Higher percentages indicate better speech perception ability.

    Time frame: From enrollment to 12 months, with assessments at 0, 6, and 12 months.

  6. Categories of Auditory Performance (CAP) Score

    The Categories of Auditory Performance (CAP) is a hierarchical rating scale assessing real-life auditory functioning. It comprises 10 categories graded from 0 to 9, where 0 = "cannot detect environmental or speech sounds" and 9 = "able to use the telephone with an unfamiliar speaker in unpredictable situations". Higher scores indicating better auditory performance.

    Time frame: From enrollment to 12 months, with assessments at 0, 6, and 12 months.

  7. Speech Intelligibility Rating (SIR) Score

    The Speech Intelligibility Rating (SIR) is a hierarchical rating scale assessing the intelligibility of a child's speech in everyday communication. It comprises 5 categories graded from 1 to 5, with higher scores indicating greater speech intelligibility.

    Time frame: From enrollment to 12 months, with assessments at 0, 6, and 12 months.

  8. Meaningful Auditory Integration Scale (MAIS/IT-MAIS) Score

    This scale includes the original MAIS version for children aged ≥3 years and the IT-MAIS (Infant-Toddler version) for children \<3 years. It is a parent-report structured interview designed to assess the child's spontaneous auditory responses in everyday environments, consisting of 10 items evaluating three domains: vocalization behavior, alerting to sounds, and deriving meaning from sound. Each item is scored from 0 to 4, yielding a total score ranging from 0 to 40. Higher scores indicate better auditory integration ability.

    Time frame: From enrollment to 12 months, with assessments at 0, 6, and 12 months.

  9. Meaningful Use of Speech Scale (MUSS) Score

    The Meaningful Use of Speech Scale (MUSS) assesses speech production and communication ability. It comprises 10 open-ended questions answered by parents/guardians, each scored 0-4). The total score ranges from 0 to 40, with higher scores indicating better speech use. Scores are often reported as percentages (score ÷ 40 × 100%).

    Time frame: From enrollment to 12 months, with assessments at 0, 6, and 12 months.

  10. Adaptive behavior measured by Adaptive Behavior Assessment System, Second Edition (ABAS-II)

    The ABAS-II is a comprehensive, norm-referenced assessment of adaptive functioning across multiple skill areas relevant to daily living. Depending on the respondent form used, it yields a General Adaptive Composite (GAC) as an overall standard score (mean = 100, SD = 15), three domain composite scores (Conceptual, Social, and Practical), and individual skill area scaled scores covering domains such as Communication, Community Use, Functional Academics, Home Living, Health and Safety, Leisure, Self-Care, Self-Direction, Social, Work (where applicable), and Motor. Higher scores consistently indicating more advanced adaptive functioning.

    Time frame: From enrollment to 12 months, with assessments at 0, 6, and 12 months.

Other outcomes

  1. Distortion Product Otoacoustic Emissions (DPOAE) Amplitude and Signal-to-Noise Ratio

    DPOAEs were recorded bilaterally at standard frequencies. For each frequency, the DPOAE amplitude (in dB SPL) and signal-to-noise ratio (SNR, in dB) were obtained. The amplitude represents the absolute sound pressure level of the distortion product response, while the SNR is the difference between the amplitude and the background noise floor at the same frequency. Higher amplitude and SNR indicate stronger outer hair cell (OHC)-mediated cochlear amplification and better cochlear function. A DPOAE response is conventionally considered present (PASS) when the SNR exceeds 6 dB.

    Time frame: From enrollment to 12 months, with assessments at 0, 6, and 12 months.

  2. Acoustic Immittance

    Acoustic immittance is measured via tympanometry using a 226-Hz probe tone. Three quantitative parameters are reported: tympanometric peak pressure (measured in daPa), peak compensated static admittance (measured in mmho), and equivalent ear canal volume (measured in mL). Results are classified as pass or fail based on standardized criteria.

    Time frame: From enrollment to 12 months, with assessments at 0, 6, and 12 months.

  3. Family Environment Survey

    Including basic family environment survey, and Index of Child Care Environment (ICCE)

    Time frame: From enrollment to 12 months, with assessments at 0, 6, and 12 months.

07

Study locations

12 sites
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

Time frame: The protocol will be available from study initiation, before the first participant is enrolled. The final version of SAP will be approved before database lock and will be shared 6 months after the primary results are published.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

Of 27 interventional studies with no phase under Hearing Loss, Bilateral, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 60. This study's planned 24 months is above that.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, last on Nov 6, 2026.

Primary completion moved twice since we started tracking on Sep 25, 2026: Aug 2028 → Nov 2028, last on Nov 6, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Aug 2028 → Nov 2028, last on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2026
First posted
Aug 19, 2026
StartEst.
Nov 15, 2026was Aug 2026
Primary completionEst.
Nov 15, 2028was Aug 2028
CompletionEst.
Nov 15, 2028was Aug 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added
Show 11 added (11 China)
  • The First People's Hospital of Foshan · Foshan, China
  • Guangzhou Women and Children's Medical Center, Guangzhou Medical University · Guangzhou, China
  • Jiangyin People's Hospital · Jiangyin, China
  • Children's Hospital of Kunming Medical University · Kunming, China
  • Liuzhou Maternal and Child Health Hospital · Liuzhou, China
  • Children's Hospital of Nanjing Medical University · Nanjing, China
  • Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, China
  • Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine · Shanghai, China
  • West China Hospital, Sichuan University · Sichuan, China
  • Taizhou People's Hospital · Taizhou, China
  • Affiliated Hospital of Yan'an University · Yan’an, China
Oct 2, 2026
Start date
Aug 31, 2026→Nov 15, 2026
moved 2 times, Oct 2, 2026 – Nov 6, 2026
Primary completion
Aug 31, 2028→Nov 15, 2028
moved 2 times, Oct 2, 2026 – Nov 6, 2026
Study completion
Aug 31, 2028→Nov 15, 2028
moved 2 times, Oct 2, 2026 – Nov 6, 2026
Enrollment
236→260
Nov 6, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011 · Shanghai, ChinaContact z•••@163.com · •••4064→z•••@163.com · •••4064
Oct 2, 2026
Show all 2 updates
  1. Nov 6, 2026
    Start date Sep 30, 2026→Nov 15, 2026
    Primary completion Sep 30, 2028→Nov 15, 2028
    Study completion Sep 30, 2028→Nov 15, 2028
    Enrollment 258→260
    + 1 other change: verification date
  2. Oct 2, 2026
    11 sites added
    Show 11 added (11 China)
    • The First People's Hospital of Foshan · Foshan, China
    • Guangzhou Women and Children's Medical Center, Guangzhou Medical University · Guangzhou, China
    • Jiangyin People's Hospital · Jiangyin, China
    • Children's Hospital of Kunming Medical University · Kunming, China
    • Liuzhou Maternal and Child Health Hospital · Liuzhou, China
    • Children's Hospital of Nanjing Medical University · Nanjing, China
    • Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, China
    • Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine · Shanghai, China
    • West China Hospital, Sichuan University · Sichuan, China
    • Taizhou People's Hospital · Taizhou, China
    • Affiliated Hospital of Yan'an University · Yan’an, China
    Start date Aug 31, 2026→Sep 30, 2026
    Primary completion Aug 31, 2028→Sep 30, 2028
    Study completion Aug 31, 2028→Sep 30, 2028
    Enrollment 236→258
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011 · Shanghai, ChinaContact z•••@163.com · •••4064→z•••@163.com · •••4064
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07774728
Responsible party
Sponsor
First posted
Aug 19, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Nov 15, 2028 (estimated)
Completion
Nov 15, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Zhili Wang
Contact
zhili_w@163.com
+86-21-53314064
Hao Wu
principal investigator · Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Hao Wu
study chair · Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion